Drugs / Nivolumab/rHuPH20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05496192 | May 2023 → Jun 2024 | melanoma, urothelial carcinoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nivolumab/rHuPH20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05496192 ↗ |
| Route | Intravenous | “Intravenous (IV) to Subcutaneous (SC)” NCT05496192 ↗ |
| Route | Subcutaneous | “Intravenous (IV) to Subcutaneous (SC)” NCT05496192 ↗ |